Reuters logo
BRIEF-Salix, Valeant and Actavis agree to stay outstanding litigation
May 17, 2017 / 11:41 AM / 4 months ago

BRIEF-Salix, Valeant and Actavis agree to stay outstanding litigation

May 17 (Reuters) - Valeant

* Statement regarding XiFaxan intellectual property litigation

* Says Salix Pharmaceuticals, Valeant and Actavis Laboratories Inc, at Actavis’ request, have agreed to stay outstanding litigation

* Says companies have agreed to extend 30-month stay regarding Actavis’ ANDA for a generic version of XiFaxan (Rifaximin) 550 mg tablets

* Says legal action is stayed through April 30, 2018 and cannot be lifted prior to Oct. 31, 2017

* Valeant says all currently scheduled litigation activities, including January 2018 trial date, have been indefinitely removed from court docket Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below